You can buy or sell Athenex and other stocks, options, ETFs, and crypto commission-free!
Athenex, Inc. Common Stock, also called Athenex, is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer.It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Read More The Oncology Innovation Platform segment involves in discovery and development of cancer supportive therapies. The Global Supply Chain Platform segment consists of manufacturing and marketing of API, medical devices, and clinical products. The Commercial Platform segment engages in manufacturing and selling of commercial pharmaceutical products. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
Buffalo, New York
52 Week High
52 Week Low
Advertising and Marketing
Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $126,000 of Shares
CEO and Chairman of the Board of Athenex Inc (NASDAQ:ATNX) Johnson Yiu Nam Lau bought 10,500 shares of ATNX on 03/20/2019 at an average price of $12 a share.
Athenex's profit and revenue disappoint
Athenex Inc. ATNX, +1.02% reported a net loss in the fourth quarter as revenue climbed, but less than analysts were expecting, and research and development costs held about steady. Athenex reported a net loss of $27.1 million, compared with a net loss for the comparable quarter a year prior of $28.3 million. The company said it had a net loss of 41 cents a share compared with a net loss of 49 cents a share. Analysts polled by Refinitiv were expecting a net loss of 21 cents a share. The pharmaceutical comp...
Yahoo FinanceMar 11
Athenex: 4Q Earnings Snapshot
BUFFALO, N.Y. (AP) _ Athenex Inc. (ATNX) on Monday reported a loss of $27.1 million in its fourth quarter. On a per-share basis, the Buffalo, New York-based company said it had a loss of 41 cents. The biopharmaceutical company posted revenue of $21.3 million in the period. For the year, the company reported that its loss narrowed to $117.4 million, or $1.82 per share. Revenue was reported as $89.1 million. Athenex shares have declined 7 percent since the beginning of the year. The stock has declined 29 ...
-$0.20 per share
-$0.41 per share